Compare Bristol-Myers Squibb Co (BMY) vs Garmin Ltd. (GRMN) Price & Performance

Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.

BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.

Garmin (GRMN) trades at $313.16, up 0.73% on the day and near its all-time high, with a bullish technical trend and strong support at $309. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.81 beating estimates of $2.30, and raised full-year guidance. Revenue growth accelerated to 11% in Q2 2026, driven by strong performance in the fitness segment, while net income margin improved to 24.47%.

The outlook remains positive given robust fundamentals and raised guidance, but risks include rich valuation multiples, potential growth deceleration, and insider selling. Analyst consensus is cautious with a hold-heavy rating, though the average price target of $318.67 suggests modest upside from current levels.